Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 1
2008 2
2009 2
2011 2
2012 2
2015 2
2016 1
2020 1
2022 1
2023 1
2024 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
Bylicki O, Tomasini P, Radj G, Guisier F, Monnet I, Ricordel C, Bigay-Game L, Geier M, Chouaid C, Daniel C, Swalduz A, Toffart AC, Doubre H, Peloni JM, Moreau D, Subtil F, Grellard JM, Castera M, Clarisse B, Martins-Lavinas PH, Decroisette C, Greillier L; GFPC. Bylicki O, et al. Among authors: peloni jm. Eur J Cancer. 2023 Apr;183:38-48. doi: 10.1016/j.ejca.2023.01.014. Epub 2023 Jan 31. Eur J Cancer. 2023. PMID: 36801605 Free article. Clinical Trial.
[Pseudo-mesothelioma revealing an apparent primary pleural melanoma].
Roche NC, Longin C, Peloni JM, Borgna M, Leyral G, Miltgen J. Roche NC, et al. Among authors: peloni jm. Presse Med. 2011 Apr;40(4 Pt 1):443-5. doi: 10.1016/j.lpm.2010.11.011. Epub 2011 Jan 15. Presse Med. 2011. PMID: 21242051 French. No abstract available.
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis.
Bronstein A, Curcio H, Monnet I, Ricordel C, Bigay-Game L, Geier M, Decroisette C, Daniel C, Guisier F, Swalduz A, Toffart AC, Doubre H, Peloni JM, Arpin D, Morel H, Veillon R, Clarisse B, Chouaïd C, Greillier L, Bylicki O; GFPC. Bronstein A, et al. Among authors: peloni jm. Clin Lung Cancer. 2025 Aug 21:S1525-7304(25)00198-6. doi: 10.1016/j.cllc.2025.08.009. Online ahead of print. Clin Lung Cancer. 2025. PMID: 40947344
17 results